Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NKp44 CRISPR/Cas9 KO Plasmid (h): sc-407295
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NKp44 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NKp44 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NKp44 Antibody (8F12): sc-59342
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NKp44 CRISPR/Cas9 KO Plasmid (h) | sc-407295 | 20 µg | $397.00 |
Overview
NCR2 encodes NKp44 (CD336), an activating natural killer (NK) cell receptor that is induced upon NK-cell activation and signals through association with the ITAM-bearing adaptor TYROBP (DAP12). NKp44 engagement by cellular or pathogen-associated ligands promotes NK-cell degranulation and cytokine secretion, integrating into innate immune surveillance pathways that shape cytotoxic responses. NCR2 expression and NKp44-mediated signaling have been studied in contexts of immune dysregulation, including inflammatory microenvironments and altered NK-cell function within cancer and chronic infection settings. As a surface receptor with inducible expression, NKp44 is also used to dissect NK-cell activation states and receptor cross-talk with other NK receptors.
NKp44 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NCR2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NCR2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NCR2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NKp44 protein expression.
This CRISPR knockout system enables efficient generation of NCR2-deficient cell models for investigation of NKp44 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NCR2 exon(s) critical for NKp44 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NCR2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NKp44 CRISPR/Cas9 KO Plasmid (h) and NKp44 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NCR2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NKp44 HDR Plasmid (h) and NKp44 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NCR2 homology arms to support homology-directed repair at defined NCR2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.